Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in nephrology.

A Cases1

  • 1Department of Nephrology, Hospital Clínic, Barcelona, Spain.

Drug News & Perspectives
|December 24, 2004
PubMed
Summary
This summary is machine-generated.

The 31st Annual Meeting of the American Society of Nephrology showcased advances in immunosuppressants, renal anemia treatments, and hypertension therapies. Further research is needed on long-term immunosuppressant use and chronic allograft nephropathy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study.

The journal of headache and pain·2025
Same author

Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia.

Drugs of today (Barcelona, Spain : 1998)·2018
Same author

Mortality due to bleeding, myocardial infarction and stroke in dialysis patients.

Journal of thrombosis and haemostasis : JTH·2018
Same author

[Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology].

Semergen·2017
Same author

Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.

Transplantation proceedings·2015
Same author

[Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2010
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

Area of Science:

  • Nephrology
  • Immunosuppression
  • Renal Transplantation

Background:

  • The 31st Annual Meeting of the American Society of Nephrology convened in Philadelphia in 1998.
  • The meeting focused on recent breakthroughs in both basic and clinical nephrology.

Purpose of the Study:

  • To present and discuss the latest scientific advancements in nephrology.
  • To highlight emerging treatments and research findings in kidney disease and transplantation.

Main Methods:

  • Presentations and discussions of clinical trial results and scientific studies.
  • Exploration of novel immunosuppressive agents and treatment protocols.
  • Review of therapeutic approaches for renal anemia, erectile dysfunction, and hypertension.

Related Experiment Videos

Main Results:

  • Newer immunosuppressants (tacrolimus, sirolimus, mycophenolate mofetil, anti-CD25 antibodies) show promise but require long-term studies.
  • Steroid withdrawal and the role of TGF-beta in chronic allograft nephropathy were key topics.
  • NESP for renal anemia, sildenafil for hemodialysis patients' erectile dysfunction, and ACE inhibitors for nondiabetic renal patients were discussed.
  • Angiotensin II receptor antagonists show potential in renal disease hypertension.
  • A hybrid cell vaccine trial for renal cell carcinoma yielded promising results.

Conclusions:

  • Long-term studies are essential for evaluating newer immunosuppressants in transplantation.
  • Further investigation into TGF-beta's role in chronic allograft nephropathy is warranted.
  • Emerging therapies offer new avenues for managing complications and diseases in nephrology patients.